LGND Ligand Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: LGND

Price (delayed)

$279.44

Market cap

$5.6B

P/E Ratio

35.37

Dividend/share

N/A

EPS

$7.9

Enterprise value

$5.94B

?
Relative Growth: Rel. Growth: 78
Relative Strength: Rel. Strength: 89
Relative Valuation: Rel. Valuation: 50
Relative Profitability: Rel. Profitability: 98

Ligand Pharmaceuticals is a biopharmaceutical company located in San Diego, California. Founded in 1987 as Progenx Inc., the company went public in 1992.

Highlights
The gross profit has surged by 55% year-on-year and by 3.1% since the previous quarter
The revenue has surged by 51% year-on-year and by 2.4% since the previous quarter
Ligand Pharmaceuticals's quick ratio has decreased by 3.3% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ligand.com
Peers: AMGN MRK BMY LLY

Key stats

What are the main financial stats of LGND

LGND stock price

How has the Ligand Pharmaceuticals stock price performed over time
Intraday
6.59%
1 week
9.48%
1 month
21.85%
1 year
143.04%
YTD
47.8%
QTD
39.96%

Financial performance

How have Ligand Pharmaceuticals's revenue and profit performed over time
Revenue
$274.48M
Gross profit
$261.5M
Operating income
$94.59M
Net income
$153.56M
Gross margin
95.3%
Net margin
55.9%
The net margin has soared by 176% YoY and by 20% from the previous quarter
The company's operating income has surged by 131% QoQ
Ligand Pharmaceuticals's operating margin has surged by 125% QoQ
The gross profit has surged by 55% year-on-year and by 3.1% since the previous quarter

Price vs fundamentals

How does LGND's price correlate with its fundamentals

Growth

What is Ligand Pharmaceuticals's growth rate over time

Valuation

What is Ligand Pharmaceuticals stock price valuation
LGND P/E details
P/E
35.37
P/B
5.59
P/S
20.24
EV/EBIT
31.17
EV/EBITDA
26.32
EV/Sales
21.63
Ligand Pharmaceuticals's EPS has increased by 23% QoQ
LGND's P/B is 133% higher than its 5-year quarterly average of 2.4 and 60% higher than its last 4 quarters average of 3.5
The equity has grown by 25% year-on-year
The price to sales (P/S) is 102% higher than the 5-year quarterly average of 10.0 and 51% higher than the last 4 quarters average of 13.4
The revenue has surged by 51% year-on-year and by 2.4% since the previous quarter

Efficiency

How efficient is Ligand Pharmaceuticals business performance
The company's return on equity has surged by 199% YoY and by 17% QoQ
Ligand Pharmaceuticals's return on sales has surged by 180% YoY and by 14% QoQ
The ROA has soared by 177% YoY and by 9% QoQ
Ligand Pharmaceuticals's ROIC has soared by 146% YoY but it has decreased by 9% from the previous quarter

Dividends

What is LGND's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LGND.

Financial health

How did Ligand Pharmaceuticals financials performed over time
The company's total assets is 186% higher than its total liabilities
The company's total assets has surged by 69% YoY
LGND's current ratio is down by 4.3% since the previous quarter
The debt is 55% less than the equity
The equity has grown by 25% year-on-year
The debt to equity has grown by 2.3% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.